Track Carisma Therapeutics Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Carisma Therapeutics Inc. Common Stock CARM Open Carisma Therapeutics Inc. Common Stock in new tab

0.000100 USD
P/E
0.00
EPS
0.19
P/B
0.00
ROE
-362.79
Beta
1.31
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 19, 2026
P/E0.00
EPS0.19
Book Value-0.02
Price to Book0.00
% Insiders26.561%
Growth
Revenue Growth12.37%
Estimates
Forward P/E0.00
Forward EPS-0.91

DCF Valuation

Tweak assumptions to recompute fair value for Carisma Therapeutics Inc. Common Stock (CARM)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Carisma Therapeutics Inc. Common Stock Logo Carisma Therapeutics Inc. Common Stock Analysis (CARM)

United States Health Care Official Website Stock

Is Carisma Therapeutics Inc. Common Stock a good investment? Carisma Therapeutics Inc. Common Stock (CARM) is currently trading at 0.000100 USD.

In terms of valuation, the stock trades at a P/E ratio of 0.00. This relatively low multiple may signal that Carisma Therapeutics Inc. Common Stock is undervalued compared to historical market norms.

Earnings Schedule: Carisma Therapeutics Inc. Common Stock is expected to release its next earnings report on May 19, 2026. The market consensus estimate for Forward EPS is -0.91.

Investor FAQ

Does Carisma Therapeutics Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Carisma Therapeutics Inc. Common Stock?

Carisma Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be May 19, 2026. The company currently has a trailing EPS of 0.19.

Company Profile

Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Exchange Ticker
NMS (United States) CARM
Historical Dividends
Year Total Dividends
2023 0.36 USD

Yearly aggregated dividends

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
March 8, 2023 0.050000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion